(1R)-2-[(6-chloropyrimidin-4-yl)amino]-1-phenylethanol | 1184850-54-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (1R)-2-[(6-chloropyrimidin-4-yl)amino]-1-phenylethanol
• 英文别名: (1R)-2-[(6-Chloropyrimidin-4-yl)amino]-1-phenylethanol
• CAS: 1184850-54-1
• 化学式: C₁₂H₁₂ClN₃O
• 分子量: 249.7
• InChiKey: JSGXBBPPOXZKRC-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  58
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-乙氧基3-三氟甲基苯硼酸 、 (1R)-2-[(6-chloropyrimidin-4-yl)amino]-1-phenylethanol 在 potassium phosphate 、 四(三苯基膦)钯 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 17.0h， 生成 (1R)-2-({6-[4-(ethyloxy)-3-(trifluoromethyl)phenyl]pyrimidin-4-yl}amino)-1-phenylethanol
  参考文献：
  名称：

  [EN] ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE
  [FR] ARYL-HYDROXYÉTHYLAMINO-PYRIMIDINES ET TRIAZINES EN TANT QUE MODULATEURS D'AMIDE D'ACIDE GRAS HYDROLASE

  摘要：

  描述了某些芳基-羟乙基氨基嘧啶和三嗪化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制备药物组合物和治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、紊乱和症状，如焦虑、疼痛、炎症、睡眠障碍、进食障碍、能量代谢障碍和运动障碍（例如多发性硬化）。还公开了合成这些化合物的方法。

  公开号：

  WO2009105220A1
• 作为产物：
  描述：

  (R)-2-phenyl-2-(trimethylsiloxy)acetonitrile 在 lithium aluminium tetrahydride 、 碳酸氢钠 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 17.0h， 生成 (1R)-2-[(6-chloropyrimidin-4-yl)amino]-1-phenylethanol
  参考文献：
  名称：

  1-Aryl-2-((6-aryl)pyrimidin-4-yl)amino)ethanols as competitive inhibitors of fatty acid amide hydrolase

  摘要：

  A series of 1-aryl-2-(((6-aryl)pyrimidin-4-yl)amino)ethanols have been found to be competitive inhibitors of fatty acid amide hydrolase (FAAH). One member of this class, JNJ-40413269, was found to have excellent pharmacokinetic properties, demonstrated robust central target engagement, and was efficacious in a rat model of neuropathic pain. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.064

文献信息

• Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase
  申请人：Apodaca Richard

  公开号：US20090264429A1

  公开（公告）日：2009-10-22

  Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

  描述了某些芳基-羟乙基氨基嘧啶和三嗪化合物，这些化合物可用作FAAH抑制剂。这些化合物可以用于制备药物组合物和治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、障碍和病况的方法，例如焦虑、疼痛、炎症、睡眠障碍、进食障碍、能量代谢障碍和运动障碍（例如多发性硬化症）。还公开了合成这些化合物的方法。
• Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
  申请人：Apodaca Richard

  公开号：US08598202B2

  公开（公告）日：2013-12-03

  Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

  本文介绍了某些芳基-羟乙基氨基嘧啶和三嗪化合物，它们可用作FAAH（脂肪酸酰胺水解酶）抑制剂。这些化合物可用于制备药物组合物和治疗由FAAH活性介导的疾病状态、疾病和情况，例如焦虑、疼痛、炎症、睡眠障碍、进食障碍、能量代谢障碍和运动障碍（如多发性硬化症）。本文还揭示了合成这些化合物的方法。
• ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP2254415A1

  公开（公告）日：2010-12-01
• US8598202B2
  申请人：——

  公开号：US8598202B2

  公开（公告）日：2013-12-03
• [EN] TREATMENT OF ENERGY UTILIZATION DISEASES<br/>[FR] TRAITEMENT DE MALADIES UTILISANT DE L'ÉNERGIE
  申请人：SUMMIT CORP PLC

  公开号：WO2010049678A2

  公开（公告）日：2010-05-06

  Described are various compounds, in particular iminosugars, for the treatment of energy utilization diseases, in particular diabetes (including type 1 diabetes, type 2 diabetes and insulin resistance) and metabolic syndrome (including any disease or disorder associated therewith, for example central obesity and elevated levels of triglycerides).